170856-29-8

Basic information

• Product Name: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate
• Synonyms: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate
• CAS NO: 170856-29-8
• Molecular Weight: 295.335
• Mol File: 170856-29-8.mol

Chemical Properties

• CAS DataBase Reference: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate(170856-29-8)
• EPA Substance Registry System: Ethyl 3-(N-tert-butyloxycarbonylamino)phenyloxyacetate(170856-29-8)

Safety Data

• Hazardous Substances Data: 170856-29-8(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 591-27-5 m-Hydroxyaniline 
• 19962-06-2 tert-butyl 3-hydroxyphenylcarbamate 
• 105-36-2 ethyl bromoacetate 

Downstream Products

• 1310744-77-4 (R)-2-(3-(((3-(carboxymethoxy)phenyl)amino)methyl)benzamido)pentanedioic acid 
• 170855-82-0 1,5-Bis-(cyclopropylcarbonylmethyl)-3-(N'-(m-(carboethoxymethoxy)phenyl)ureido)-1H-1,5-benzodiazepine-2,4(3H,5H)-dione 
• 58559-52-7 3-aminophenoxyacetic acid ethyl ester 

Relevant articles and documents

KIF18A INHIBITORS

Amide compounds of formula (I): and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of Kinesin Motor Protein KIF18A, such as cancer, psoriasis, atopic dermatitis, an autoimmune disorder, or inflammatory bowel disease, and the like.

Structure-based design of a new series of d-glutamic acid based inhibitors of bacterial UDP-N-acetylmuramoyl-l-alanine: D-glutamate ligase (MurD)

MurD ligase is one of the key enzymes participating in the intracellular steps of peptidoglycan biosynthesis and constitutes a viable target in the search for novel antibacterial drugs to combat bacterial drug-resistance. We have designed, synthesized, and evaluated a new series of d-glutamic acid-based Escherichia coli MurD inhibitors incorporating the 5-benzylidenethiazolidin-4- one scaffold. The crystal structure of 16 in the MurD active site has provided a good starting point for the design of structurally optimized inhibitors 73-75 endowed with improved MurD inhibitory potency (IC50 between 3 and 7 μM). Inhibitors 74 and 75 showed weak activity against Gram-positive Staphylococcus aureus and Enterococcus faecalis. Compounds 73-75, with IC 50 values in the low micromolar range, represent the most potent d-Glu-based MurD inhibitors reported to date.

Benzodiazepine derivative

A benzodiazepine derivative of the formula (I): STR1 wherein R 1 is a bond, --CH 2 --, --CH 2 O--, --SCH 2 -- or a group of the formula: STR2 R 2 is a lower alkyl, --COOR 5, --CONH(CH 2) n COOR 5, --CONHSO 2 R 5, --SO 2 NHCOR 5, or an optionally substituted heterocyclic group (R 5 is a hydrogen atom, lower alkyl or benzyl and n is an integer of 1 to 5); R 3 is a bond, --CO-- or --CONH--; and R 4 is an optionally substituted heterocyclic group, optionally substituted lower alkyl, optionally substituted lower cycloalkyl, optionally substituted aryl, or lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, which has a high affinity for gastrin receptors and/or CCK-B receptors but not for CCK-A receptors, and is useful for treating diseases associated with gastrin receptors and/or CCK-B receptors without inducing the side effects associated with CCK-A receptors.

Quinazolines: Combined type 3 and 4 phosphodiesterase inhibitors

A series of quinazolines has been prepared and evaluated for its ability to inhibit cyclic AMP phosphodiesterase type 3, type 4A, 4B and 4D. The most potent inhibitors showed IC50 values in the nanomolar range for type 3 and type 4 isoforms and bind with high affinity to the [3H]rolipram binding site. These quinazolines represent a new family of potent mixed PDE 3 / 4 inhibitors and are expected to have a therapeutic potential.

Potent and subtype-selective CCK-B/gastrin receptor antagonists: 2,4-dioxo-1,5-benzodiazepines with a plane of symmetry

A series of CCK-B/gastrin receptor antagonists, 2,4-dioxo-1,5-benzodiazepine derivatives with a plane of symmetry, were designed, synthesized, and evaluated for antagonistic activity. Structure-activity relationship studies revealed that carbonylmethyl groups at both N-1 and N-5 positions and hydrophilic groups, such as the carboxyl group on the benzene ring attached to the ureido group at the C-3 position, brought about potent affinity and subtype selectivity for CCK-B/gastrin receptors. Several compounds showed excellent in vivo inhibition of gastric acid secretion induced by pentagastrin in anesthetized rats.